Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense TC with Pegfilgrastim for Adjuvant Breast Cancer
NCT01671319Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jun 2011
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in breast cancer, sponsored by University of Wisconsin–Madison. Primary endpoint: Feasibility for Dose-dense TC Therapy: Number of Participants Receiving at Least 90% of Total Dose of Therapy at 10 weeks. Started Jun 2011; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01671319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01671319.